-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 24, Joincare Pharmaceuticals issued an announcement stating that the clinical trial application of the "recombinant new coronavirus fusion protein vaccine" developed by its holding subsidiary Livzumab was approved by the State Food and Drug Administration.
Recombinant new coronavirus fusion protein vaccine (hereinafter referred to as: V-01) has been developed since July 2020.
According to LSHTM tracker information, as of March 22, 2021, a total of 86 new crown vaccine products worldwide are in clinical trials, of which 13 products have been approved for marketing or emergency use authorization.